<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Cell Cycle</journal-id>
<journal-id journal-id-type="iso-abbrev">Cell Cycle</journal-id>
<journal-id journal-id-type="publisher-id">KCCY</journal-id>
<journal-id journal-id-type="publisher-id">kccy20</journal-id>
<journal-title-group>
<journal-title>Cell Cycle</journal-title>
</journal-title-group>
<issn pub-type="ppub">1538-4101</issn>
<issn pub-type="epub">1551-4005</issn>
<publisher>
<publisher-name>Taylor &amp; Francis</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29578365</article-id>
<article-id pub-id-type="pmc">5969551</article-id>
<article-id pub-id-type="publisher-id">1450029</article-id>
<article-id pub-id-type="doi">10.1080/15384101.2018.1450029</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Capicua tumor suppressor: a gatekeeper of Ras signaling in development and cancer</article-title>
<alt-title alt-title-type="running-authors">L. SIMÓN-CARRASCO ET AL.</alt-title>
<alt-title alt-title-type="running-title">CELL CYCLE</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3281-8144</contrib-id>
<name>
<surname>Simón-Carrasco</surname>
<given-names>Lucía</given-names>
</name>
<xref ref-type="aff" rid="af0001">
<sup>a</sup>
</xref>
<xref ref-type="author-notes" rid="afn0001">
<sup>*</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2765-9289</contrib-id>
<name>
<surname>Jiménez</surname>
<given-names>Gerardo</given-names>
</name>
<xref ref-type="aff" rid="af0002">
<sup>b</sup>
</xref>
<xref ref-type="aff" rid="af0003">
<sup>c</sup>
</xref>
<xref ref-type="corresp" rid="an0001"></xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1480-2624</contrib-id>
<name>
<surname>Barbacid</surname>
<given-names>Mariano</given-names>
</name>
<xref ref-type="aff" rid="af0001">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3205-456X</contrib-id>
<name>
<surname>Drosten</surname>
<given-names>Matthias</given-names>
</name>
<xref ref-type="aff" rid="af0001">
<sup>a</sup>
</xref>
<xref ref-type="corresp" rid="an0002"></xref>
</contrib>
<aff id="af0001"><label>a</label><institution>Molecular Oncology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO)</institution>, Melchor Fernández Almagro 3, Madrid, <country>Spain</country></aff>
<aff id="af0002"><label>b</label><institution>Institut de Biologia Molecular de Barcelona-CSIC</institution>, <addr-line>Parc Científic de Barcelona</addr-line>, Barcelona, <country>Spain</country></aff>
<aff id="af0003"><label>c</label><institution>ICREA</institution>, <addr-line>Pg. Lluís Companys 23</addr-line>, Barcelona, <country>Spain</country></aff>
</contrib-group>
<author-notes>
<corresp id="an0001">Gerardo Jiménez <email>gjcbmc@ibmb.csic.es</email>, Centro Nacional de Investigaciones Oncológicas (CNIO), Melchor Fern´ndez Almagro 3, 28029 Madrid, Spain</corresp>
<corresp id="an0002">Matthias Drosten <email>mdrosten@cnio.es</email>, Centro Nacional de Investigaciones Oncológicas (CNIO), Melchor Fern´ndez Almagro 3, 28029 Madrid, Spain</corresp>
<fn id="afn0001">
<label>*</label>
<p>Current address: Biotech Research and Innovation Centre (BRIC), University of Copenhagen, Ole Maaløes Vej 5, 2200 Copenhagen, Denmark.</p>
</fn>
</author-notes>
<pub-date pub-type="collection">
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>18</day>
<month>5</month>
<year>2018</year>
</pub-date>
<volume>17</volume>
<issue>6</issue>
<fpage seq="4">702</fpage>
<lpage>711</lpage>
<history>
<date date-type="received">
<day>7</day>
<month>11</month>
<year>2017</year>
</date>
<date date-type="rev-recd">
<day>23</day>
<month>2</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>3</day>
<month>3</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>© 2018 Taylor &amp; Francis</copyright-statement>
<copyright-year>2018</copyright-year>
<copyright-holder>Taylor &amp; Francis</copyright-holder>
</permissions>
<self-uri content-type="pdf" xlink:href="kccy-17-06-1450029.pdf"></self-uri>
<abstract>
<title>ABSTRACT</title>
<p>The transcriptional repressor Capicua (CIC) has emerged as an important rheostat of cell growth regulated by RAS/MAPK signaling. Cic was originally discovered in <italic>Drosophila</italic>, where it was shown to be inactivated by MAPK signaling downstream of the RTKs Torso and EGFR, which results in signal-dependent responses that are required for normal cell fate specification, proliferation and survival of developing and adult tissues. CIC is highly conserved in mammals, where it is also negatively regulated by MAPK signaling. Here, we review the roles of CIC during mammalian development, tissue homeostasis, tumor formation and therapy resistance. Available data indicate that CIC is involved in multiple biological processes, including lung development, liver homeostasis, autoimmunity and neurobehavioral processes. Moreover, CIC has been shown to be involved in tumor development as a tumor suppressor, both in human as well as in mouse models. Finally, several lines of evidence implicate CIC as a determinant of sensitivity to EGFR and MAPK pathway inhibitors, suggesting that CIC may play a broader role in human cancer than originally anticipated.</p>
</abstract>
<kwd-group kwd-group-type="author">
<title>KEYWORDS</title>
<kwd>CIC</kwd>
<kwd>Ras signaling</kwd>
<kwd>T-ALL</kwd>
<kwd>mouse models</kwd>
<kwd>Etv4</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>
<named-content content-type="funder-name">European Research Council</named-content>
<named-content content-type="funder-identifier">10.13039/501100000781</named-content>
</funding-source>
<award-id>ERC-AG/250297-RAS AHEAD, ERC-AG/695566-THERACAN, S2011/BDM-2470/ONCOCYCLE, GC16173694BARB, SAF2014-59864-R, BFU2014-52863-P</award-id>
</award-group>
<funding-statement>This work has been supported by grants from the Fundació La Marató de TV3 (20131730/1) to G.J. and M.B., from the European Research Council (ERC-AG/250297-RAS AHEAD and ERC-AG/695566-THERACAN), the Autonomous Community of Madrid (S2011/BDM-2470/ONCOCYCLE) and the Foundation of the Asociación Española contra el Cáncer (AECC) (GC16173694BARB) to M.B, and the Spanish Ministry of Economy and Competitiveness (SAF2014-59864-R to M.B. and BFU2014-52863-P to G.J.). M.B. is the recipient of an Endowed Chair from the AXA Research Fund. L.S.C. has been supported by a fellowship from the Programa de Formación de Personal Investigator (FPI) of the Spanish Ministry of Economy and Competitiveness.</funding-statement>
</funding-group>
<counts>
<fig-count count="4"></fig-count>
<table-count count="1"></table-count>
<ref-count count="72"></ref-count>
<page-count count="10"></page-count>
</counts>
</article-meta>
</front>
</article>
</pmc-articleset>